Residential College | false |
Status | 已發表Published |
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy | |
Peng, Yingjun; Fu, Shengyu; Zhao, Qi | |
2022-10 | |
Source Publication | Journal of leukocyte biology |
ISSN | 1938-3673 |
Volume | 112Issue:4Pages:823-834 |
Abstract | Diverse cytokines and their receptors on immune cells constitute a highly complex network in the immune system. Some therapeutic cytokines and their derivatives have been approved for cancer treatment. IL-15 is an immune-regulating cytokine with multiple functions, among which the function of activating the immunity of cancer patients has great potential in cancer immunotherapy. In this review, we introduce the functions of IL-15 and discuss its role in regulating the immune system in different immune cells. Meanwhile, we will address the applications of IL-15 agonists in cancer immunotherapy and provide prospects for the next generation of therapeutic designs. Although many challenges remain, IL-15 agonists offer a new therapeutic option in the future direction of cancer immunotherapy. |
DOI | 10.1002/JLB.5MR0422-506R |
URL | View the original |
Indexed By | SCIE |
WOS ID | WOS:000803428800001 |
Scopus ID | 2-s2.0-85130616444 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences DEPARTMENT OF BIOMEDICAL SCIENCES |
Corresponding Author | Zhao, Qi |
Affiliation | Faculty of Health Science, University of Macau |
Recommended Citation GB/T 7714 | Peng, Yingjun,Fu, Shengyu,Zhao, Qi. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of leukocyte biology, 2022, 112(4), 823-834. |
APA | Peng, Yingjun., Fu, Shengyu., & Zhao, Qi (2022). 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy. Journal of leukocyte biology, 112(4), 823-834. |
MLA | Peng, Yingjun,et al."2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy".Journal of leukocyte biology 112.4(2022):823-834. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment